These are the stocks posting the largest moves before the bell.Market Insiderread more
An oil processing facility at Abqaiq and the nearby Khurais oil field was attacked on Saturday.Marketsread more
"There is reason to believe that we know the culprit," Trump said in a post on Twitter.Politicsread more
An extended Saudi oil outage could push Brent crude prices north of $75 per barrel, Goldman Sachs warned clients.Marketsread more
As investors worry about oil supply, airline and cruise ship stocks are getting hit on Monday, while some energy stocks are shooting upward.Marketsread more
Here are the biggest calls on Wall Street on MondayInvestingread more
Brent crude surged by as much as 19.5% to reach $71.95 per barrel on Monday, the biggest intra-day jump since the Gulf War in 1991.Oilread more
U.S. stock futures are under pressure Monday as oil prices spike after Saturday's coordinated strikes on key Saudi oil interests.Marketsread more
In the past few weeks, the S&P 500 has waged a 6% rally, pulling within 1% of its late-July record high by Friday's close.Trading Nationread more
The strike, depending on its length, could easily cost GM hundreds of millions of dollars. The last time the union declared a strike at GM was in 2007.Autosread more
Consumers in the U.S. prefer Apple's more expensive models, while the standard iPhone 11 appears to be more attractive to buyers in China, according to Kuo.Technologyread more
swine fever@ (Recasts with ministry of agriculture's statement)
BEIJING, June 13 (Reuters) - China's ministry of agriculture said on Thursday a company which claimed a natural compound was effective in preventing African swine fever did not have government approval to research the virus and its assertions were not scientifically sound.
Shopping mall operator Guangdong Highsun Group Co was questioned by the Shenzhen Stock Exchange earlier on Thursday after this week announcing it was backing development of an African swine fever vaccine.
Beijing strictly regulates research on, and handling of, the virus.
Highsun said on Tuesday it would spend 900 million yuan ($130.09 million), or 26% of its 2018 net assets, on supporting research into a natural compound it said had been shown to prevent the disease which is deadly to pigs and ravaging herds across Asia.
But the ministry said it had not received a research application and without experimental data, the claim that a polysaccharide injection is effective in preventing the virus lacked scientific proof.
Researchers around the world have been trying for years to develop a vaccine against African swine fever without success.
Highsun said that preliminary research had found the polysaccharide to be 92% effective in preventing the disease in clinical trials - an announcement which triggered a 10% surge in its shares on Wednesday, leading to a trading suspension.
The Shenzhen exchange said it was seeking clarity on several issues, including additional data regarding the vaccine's effectiveness and whether the researchers had government approval to conduct research on the virus.
An official from Highsun, who asked not to be identified, said the company was preparing a response to the exchange's questions and declined to comment further.
African swine fever kills almost all the pigs it infects. The breeding herd in China, the world's top pork producer, has declined by a record 24% owing to the disease, the agriculture ministry said on Thursday.
The Bureau of Agriculture and Rural Affairs for Hainan province said on its website on Thursday that it had supported a research team that had isolated a polysaccharide compound from tropical plants which had shown a "certain preventive effect" against African swine fever.
However, it said more research was needed in areas including the possible impact of virus mutation and the safety, stability and feasibility of industrial production of the compound.
It is not clear if the bureau was referring to the same team backed by Highsun and it did not answer calls for a comment on the statement.
Highsun's shares rose 7.3% to 3.38 yuan ($0.49) a share after resuming trading on Thursday. ($1 = 6.9185 Chinese yuan renminbi) (Reporting by Dominique Patton and Beijing Newsroom; Meg Shen in Hong Kong; editing by Christian Schmollinger and Kirsten Donovan)